ArticleGlomerular diseases
Cardiometabolic Risk, Evaluation, and Control in Lupus Nephritis.
Article in Glomerular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lupus nephritis (LN) is associated with atherosclerotic cardiovascular disease but early recognition of cardiometabolic risk in patients with LN can facilitate risk optimization with disease-modifying strategies. To identify potential gaps in cardiometabolic risk management in LN in real-world practice, we aimed to evaluate the prevalence and trend in cardiometabolic risk, evaluation, and control. Methods: We performed a single-center, cross-sectional study of all adults with biopsy-confirmed LN between 2011 and 2022 to (1) assess the prevalence of cardiometabolic risks (age, sex, diabetes mellitus, hypertension, hyperlipidemia, ischemic heart disease [IHD], reduced kidney function [estimated glomerular filtration rate, estimated glomerular filtration rate <60 mL/min/1.73 m Results: We evaluated 326 adults with LN (median age 42.0 years [interquartile range: 30.9, 52.7]). Across the 3 time periods, reduced kidney function was most frequent in 2011-2014. Hypertension and renin-angiotensin system blocker use were lowest in 2019-2022 (23.4% and 30.9%, respectively), while 38.0% achieved BP <130/80 mm Hg without significant change across time periods. Glycemic evaluation was least frequent in 2019-2022 (78.7%) compared to earlier time periods. Achievement of glycemic targets of fasting glucose <6.1 mmol/L and HbA1c ≤7% were 70.0% and 95.1%, respectively, without significant change across the time periods. Lipid evaluation was performed in 75.8% but only 32.0% achieved low-density lipoprotein-cholesterol <2.6 mmol/L. There was no significant change in the prevalence of lipid evaluation or control over time. Conclusion: Glycemic assessment and optimization of BP and lipid treatment to achieve guideline-recommended targets represent opportunities to improve cardiometabolic risk management in LN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.